Document Detail

NeuroThera(®) Efficacy and Safety Trial - 3 (NEST-3): a double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study to assess the safety and efficacy of transcranial laser therapy with the NeuroThera(®) Laser System for the treatment of acute ischemic stroke within 24 h of stroke onset.
MedLine Citation:
PMID:  23013107     Owner:  NLM     Status:  Publisher    
RATIONALE: Transcranial laser therapy is undergoing clinical trials in patients with acute ischemic stroke. The NeuroThera(®) Efficacy and Safety Trial-1 was strongly positive for 90-day functional benefit with transcranial laser therapy, and post hoc analyses of the subsequent NeuroThera(®) Efficacy and Safety Trial-2 trial suggested a meaningful beneficial effect in patients with moderate to moderately severe ischemic stroke within 24 h of onset. These served as the basis for the NeuroThera(®) Efficacy and Safety Trial-3 randomized controlled trial. AIM: The purpose of this pivotal study was to demonstrate safety and efficacy of transcranial laser therapy with the NeuroThera(®) Laser System in the treatment of subjects diagnosed with acute ischemic stroke. DESIGN: NeuroThera(®) Efficacy and Safety Trial-3 is a double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study that will enroll 1000 subjects at up to 50 sites. All subjects will receive standard medical management based on the American Stroke Association and European Stroke Organization Guidelines. In addition to standard medical management, both groups will undergo the transcranial laser therapy procedure between 4·5 and 24 h of stroke onset. The study population will be randomized into two arms: the sham control group will receive a sham transcranial laser therapy procedure and the transcranial laser therapy group will receive an active transcranial laser therapy procedure. The randomization ratio will be 1:1 and will be stratified to ensure a balanced subject distribution between study arms. STUDY OUTCOMES: The primary efficacy end point is disability at 90 days (or the last rating), as assessed on the modified Rankin Scale, dichotomized as a success (a score of 0-2) or a failure (a score of 3 to 6).
J A Zivin; R Sehra; A Shoshoo; G W Albers; N M Bornstein; B Dahlof; S E Kasner; G Howard; A Shuaib; J Streeter; S P Richieri; W Hacke;
Related Documents :
19755887 - Use of a discharge facilitator improves recall of emergency department discharge instru...
22933577 - The evaluation of primary focal hyperhidrosis patients in terms of alexithymia.
16477567 - Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients r...
24044617 - Responsiveness to change for the brazilian scale of oral health outcomes for 5-year-old...
16356437 - Noninvasive therapy with helium-oxygen for severe bronchiolitis.
23229767 - Once-daily memantine : a guide to its use in moderate to severe alzheimer's disease in ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-27
Journal Detail:
Title:  International journal of stroke : official journal of the International Stroke Society     Volume:  -     ISSN:  1747-4949     ISO Abbreviation:  Int J Stroke     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101274068     Medline TA:  Int J Stroke     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization.
UCSD/VA, San Diego, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  No association between COL3A1, COL6A1 or COL12A1 gene variants and range of motion.
Next Document:  Thermodynamic Investigations Using Molecular Dynamics Simulations with Potential of Mean Force Calcu...